UNAIDS' Sidibe calls for increased access to HIV drugs at IAS conference opening

UNAIDS Executive Director Michel Sidibe on Sunday at the opening of the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Rome "called ... for an increase in access to drugs that help treat or prevent the spread of the disease, saying it is 'morally wrong' to keep millions of people off lifesaving medication," the Associated Press/Boston Globe reports (7/18).

Sidibe "said the gap in access to HIV treatment should be closed both within and between countries" and "called for better delivery on the ground, a reduction in the number of years it now takes to turn scientific discoveries into actual progress for the poor, and increased cooperation among states, pharmaceutical companies and international organizations," the Associated Press writes.

"Sidibe also said any trade agreement that would limit access to medication, especially generic ones, should be opposed," the news agency states. IAS President and Conference Chair Elly Katabira shared that concern, saying, "I hope our voice will be heard in asking that access to all drugs, including generic drugs, will not be diminished by new laws or regulations anywhere in the world," according to the AP (7/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Sweden becomes first country to meet global HIV targets